

Special Issue

Recent Scientific Advances in Vaccines for Shigella

Message from the Guest Editors

Diarrheal disease is a pressing global health issue, especially for children in low- to middle-income countries. Shigella is a leading cause of diarrhea-related mortality in children under 5 and ranks second across all age groups. It's also linked to Traveler's diarrhea and post-infectious conditions like reactive arthritis and irritable bowel syndrome (IBS). Antibiotics are commonly used for shigellosis, but the rise of antimicrobial-resistant (AMR) Shigella strains threatens treatment. The WHO designates Shigella spp. as Priority Pathogens for new therapeutics. A viable solution lies in developing an effective Shigella vaccine. Numerous vaccine candidates, including conjugate, outer membrane vesicles, recombinant subunit, and live attenuated vaccines, are in clinical testing. The preclinical pipeline offers additional candidates like killed whole-cell and multi-pathogen vaccines. This Special Issue welcomes contributions on Shigella vaccine development, encompassing preclinical and clinical insights and assay development for evaluating vaccine efficacy and potential protection indicators.

Guest Editors

Dr. Akamol Suvarnapunya

Dr. Kristen A Clarkson

Dr. Renee Laird

Dr. August Louis Bourgeois

Deadline for manuscript submissions

30 June 2025



Vaccines

an Open Access Journal
by MDPI

Impact Factor 5.2
CiteScore 8.9
Indexed in PubMed



mdpi.com/si/198784

Vaccines
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 5.2
CiteScore 8.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,
University of Georgia, Athens, GA 30602-7387, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Immunology) / CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.6 days after submission; acceptance to publication is undertaken in 3.3 days (median values for papers published in this journal in the second half of 2024).